| Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. | |
| | |
MedLine Citation:
|
PMID: 20920045 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIMS: The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes (T2D) achieve glycaemic targets. This study compares the efficacy and safety of insulin lispro protamine suspension (ILPS) and insulin glargine in insulin-naive patients with T2D and inadequate control on oral antihyperglycaemic medication (OAM). MATERIALS AND METHODS: An open-label, randomized, multicentre, multinational 24-week study of 471 patients receiving ≥2 OAMs for ≥3 months with a body mass index between 25 and 45 kg/m(2) and HbA1c 7.5-10.0% was conducted. ILPS was injected once or twice daily vs. glargine injected once daily plus prestudy OAMs. Primary objective compared the HbA1c change from baseline. RESULTS: HbA1c change from baseline to endpoint was similar in both groups [-1.46% (ILPS) and -1.41% (glargine)]. Least-squares mean difference (95% CI) for HbA1c (-0.05 [-0.21, 0.11]%), glycaemic variability (0.06 [-0.06, 0.19] mmol/l) and weight change (-0.01 [-0.61, 0.59] kg) showed non-inferiority (margins of 0.4%, 0.8 mmol/l and 1.5 kg, respectively). Percentages of patients achieving HbA1c <7.0% were 43.8% ILPS and 41.2% glargine. Mean daily insulin dose was 0.39 vs. 0.35 U/kg (p = 0.02) and weight gain was 1.04 vs. 1.07 kg for ILPS vs. glargine (p = 0.98). Overall hypoglycaemia (episodes/patient/year) was similar for ILPS and glargine (24.2 ± 28.8 vs. 23.0 ± 30.9); nocturnal (6.1 ± 10.6 vs. 4.1 ± 9.4, p < 0.001) rates were higher for ILPS. Severe hypoglycaemia was higher for ILPS vs. glargine (n = 9 vs. n = 2; p = 0.04). CONCLUSIONS: At endpoint, ILPS was non-inferior to glargine in HbA1c change from baseline, but associated with increased risk of hypoglycaemia. |
| | |
Authors:
|
K Strojek; C Shi; M A Carey; S J Jacober |
Related Documents
:
|
1563245 - Hyperglycaemia, hypoglycaemia, and blood glucose control in diabetes: symptom perceptio... 7957405 - Uncooked cornstarch treatment for hepatic phosphorylase kinase deficiency. 17097185 - Improving metabolic control in sub-optimally controlled subjects with type 1 diabetes: ... 2527685 - Hypoglycaemic brittle diabetes successfully managed by social worker intervention. 3074295 - Glomerular dysfunction in diabetic nephropathy. 9920155 - Association between low-density lipoprotein composition and its metabolism in non-insul... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 12 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 916-22 Citation Subset: IM |
Copyright Information:
|
© 2010 Eli Lilly and Company. |
Affiliation:
|
Department of Internal Diseases, Diabetology and Nephrology, Silesian Medical University, Zabrze, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-c...
Next Document: Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabe...